medigraphic.com

2011, Número 2

<< Anterior Siguiente >>

Rev Educ Bioquimica 2011; 30 (2)


El glutation y su asociación con las enfermedades neurodegenerativas, la esquizofrenia, el envejecimiento y la isquemia cerebral

Martínez-Sámano J, Torres-Durán PV, Juárez-Oropeza MA

Idioma: Español
Referencias bibliográficas: 34
Paginas: 56-67
Archivo PDF: 467.98 Kb.


RESUMEN

Las enfermedades neurodegenerativas, la esquizofrenia, el envejecimiento y la isquemia cerebral se asocian, en diferentes estadios de su desarrollo, con la existencia de estrés oxidativo; los antioxidantes constituyen un eje de protección ante la producción de especies reactivas, éstas incluyen las de tipo enzimático y las no enzimáticas; el glutatión en su forma reducida es un tipo de defensa no enzimática, y es una de las primeras líneas de defensa ante el daño oxidante. Las funciones biológicas del glutatión involucran su participación como: antioxidante, neuromodulador, detoxificante, por lo que su deficiencia es importante en la fisiopatogenia de las enfermedades anteriormente mencionadas, ya que en diferentes etapas de su desarrollo se encuentra una disminución importante en los niveles cerebrales de este metabolito. El conocimiento del metabolismo del glutatión en el cerebro es necesario para comprender la progresión e incluso el desarrollo de las enfermedades asociadas a la neurodegeneración.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Sistema Nacional de Información en Salud. Estadísticas 2000-2008. www.sinais.salud.gob.mx, accesado el día 11 abril 2011.

  2. Castrejón Sosa M (2007) Radicales libres y sistemas antioxidantes. En: Bioquímica: un enfoque básico aplicado a las ciencias de la vida. Editores: Diaz-Zagoya JC, Juárez-Oropeza MA. McGraw-Hill Interamericana, México. pp 611-628.

  3. Halliwell B (2006) Oxidative stress and neurodegeneration: where are we now? J Neurochem 97:1634-1658.

  4. Halliwell B, Gutteridge JMC (2007) Free radicals in biology and medicine. Fourth Edition. Oxford University Press, New York, USA, p. 851.

  5. Ballatori N, Krance SM, Notenboom S, Shi S, Tieu K, Hammond CL (2009) Glutathione dysregulation and the etiology and progression of human diseases. Biol Chem 390:191-214.

  6. Franco R, Cidlowski JA (2009) Apoptosis and glutathione: beyond an antioxidant. Cell Death Differ 16:1303-1314.

  7. McEligot AJ, Yang S, Meyskens FL (2005) Redox regulation by intrinsic species and extrinsic nutrients in normal and cancer cells. Annu Rev Nutr 25: 261-295.

  8. Dringen R, Gutterer JM, Hirrlinger J (2000) Glutathione metabolism in brain, metabolic interaction between astrocytes and neurons in the defense against reactive oxygen species. Eur J Biochem 267: 4912-4916.

  9. Aoyama K, Watabe M, Nakaki T (2008) Regulation of neuronal glutathione synthesis. J Pharmacol Sci 108: 227-238.

  10. Takizawa S, Matsushima K, Shinohara Y, Ogawa S, Komatsu N, Utsonomiya H, Watanabe K (1994) Immunohistochemical localization of glutathione peroxidase in infarcted human brain. J Neurol Sci 122:66-73.

  11. Janaky R, Ogita K, Pasqualotto BA, Bains JS, Oja SS, Yoneda Y, Shaw CA (1999) Glutathione and signal transduction in the mammalian CNS. J Neurochem 73: 889-902.

  12. Farooqui T, Farooqui AA. (2011) Lipid-Mediated Oxidative Stress and Inflammation in the Pathogenesis of Parkinson’s Disease. Parkinsons Dis doi:10.4061/2011/247467.

  13. Martin HL, Teismann P (2009) Glutathione: a review on its role and significance in Parkinson´s disease. FASEB J 23:3263-3272.

  14. Bain JS, Shaw CA (1997) Neurodegenerative disorders in humans: the role of glutathione in oxidative stress-mediated neuronal death. Brain Res Rev 25:335-358.

  15. Heales SJ, Lam AA, Duncan AJ, Land JM (2004) Neurodegeneration or neuroprotection: the pivotal role of astrocytes. Neurochem Res 29:513-519.

  16. Liu H, Wang H, Shenvi S, Hagen TM, Liu RM (2004) Glutathione metabolism during aging and in Alzheimer disease. Ann N Y Acad Sci 1019:346-349.

  17. Ghosh N, Ghosh R, Mandal SC (2011) Antioxidant protection: A promising therapeutic intervention in neurodegenerative disease. Free Radic Res DOI: 10.3109/10715762.2011.574290.

  18. Bento-Abreu A, Van Damme P, Van Den Bosch L, Robberecht W (2010) The neurobiology of the amyotrophic lateral sclerosis. Eur J Neurosci 31:2247-2265.

  19. Do QM, Cabungcal JH, Frank A, Steullet P, Cuenod M (2009) Redox dysregulation, neurodevelopment, and schizophrenia. Curr Opin Neurobiol 19: 220-230.

  20. Gawryluk JW, Wang JF, Andreazza AC, Shao L, Young LT (2011) Decreased levels of glutathione, the major brain antioxidant, in postmortem prefrontal cortex from patients with psychiatric disorders. Int J Neuropsychopharmacol 14: 123–130.

  21. Raffa M, Mechri A, Othman LB, Fendri C, Gaha L, Kerkeni A (2009) Decreased glutathione levels and antioxidant enzyme activities in untreated and treated schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 33: 1178–1183.

  22. Micó JA, Rojas-Corrales MO, Gibert-Rahola J, Parellada M, Moreno D, Fraguas D, Graell M, Gil J, Irazusta J, Castro-Fornieles J, Soutullo C, Arango C, Otero S, Navarro A, Baeza I, Martínez-Cengotitabengo M, González-Pinto A (2011) Reduced antioxidant defense in early onset first-episode psychosis: a casecontrol study. BMC Psychiatry 11:26.

  23. Gravina P, Spoletini I, Masini S, Valentini A, Vanni D, Paladini E, Bossù P, Caltagirone C, Federici G, Spalletta G, Bernardini S (2011) Genetic polymorphisms of glutathione Stransferases GSTM1, GSTT1, GSTP1 and GSTA1 as risk factors for schizophrenia. Psychiatry Res 187:454-456.

  24. Allen CL, Bayraktutan U (2009) Oxidative stress and its role in the pathogenesis of ischaemic stroke. Int J Stroke 4: 461-470.

  25. Mizui T, Kinouchi H, Chan P (1992) Depletion of brain glutathione by buthionine sulfoximine enhances cerebral ischemic injury in rats. Am J Physiol 262: 313-317.

  26. Riddle DR (2007) Brain Aging: Models, Methods, and Mechanisms. Frontiers in Neuroscience. CRC Press, Boca Raton, Florida, USA.

  27. Strehler EE (2010) Plasma membrane Ca2+- ATPases: Targets of oxidative stress in brain aging and neurodegeneration. World J Biol Chem 26:271-280.

  28. Hernández-Corbacho MJ, Jenkins RW, Clarke CJ, Hannun YA, Obeid LM, Snider AJ, Siskind LJ (2011) Accumulation of Long-Chain Glycosphingolipids during aging is prevented by caloric restriction. PLoS One 6:e20411.

  29. Friedman M (1994) Improvement in the safety by foods by SH-containing amino acids and peptides. J Agric Food Chem 42: 3-20.

  30. Deana OM, van den Buuse M, Berka M, Copolova DL, Mavrosa C, Bush AI ( 2011) N-acetyl cysteine restores brain glutathione loss in combined 2-cyclohexene-1-one and d-amphetamine-treated rats: Relevance to schizophrenia and bipolar disorder. Neurosci Lett doi:10.1016/j.neulet.2011.05.027.

  31. Brambilla D, Mancuso C, Scuderi MR, Bosco P, Cantarella G, Lempereur L, Benedetto G, Pezzino S, Bernardini R (2008) The role of antioxidant supplement in immune system, neoplastic, and neurodegenerative disorders: a point of view for an assessment of the risk/benefit profile. Nutr J 30:7-29.

  32. Halliwell B (2011) Free radicals and antioxidants – quo vadis? Trends Pharmacol Sci 32:125-130.

  33. Lee HP, Zhu X, Casadesus G, Castellani RJ, Nunomura A, Smith MA, Lee HG, Perry G (2010) Antioxidant approaches for the treatment of Alzheimer disease. Expert Rev Neurother 10:1201-1208.

  34. Surendran S, Rajasankar S (2010) Parkinson´s disease: oxidative stress and therapeutic approaches. Neurol Sci 31:531-540.




2020     |     www.medigraphic.com